Tazobactum%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-tazobactam ## Overview Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. It is active against many Gram-positive, Gram-negative, and anaerobic bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections (including diabetic foot infections) * Community-acquired pneumonia * Hospital-acquired pneumonia (including ventilator-associated pneumonia) * Febrile neutropenia (as part of combination therapy) ## Adult Dosing * **Standard Dose:** 3.375 grams IV every 6 hours or 4.5 grams IV every 8 hours. * **Dosing Interval:** Typically every 6 or 8 hours, depending on the chosen daily dose (e.g., 13.5 g/day or 18 g/day). * **Duration:** Varies based on infection severity and clinical response, generally 7-14 days. * **Maximum Daily Dose:** 18 grams (piperacillin 16 g / tazobactam 2 g) per day. * **Extended Infusion:** 3.375 grams or 4.5 grams IV infused over 30-60 minutes. Extended infusion may be preferred for critically ill patients to achieve higher drug concentrations. ## Pediatric Dosing * **Children < 2 years:** Dosing is based on piperacillin component per kilogram of body weight. Consult specific institutional protocols or pediatric infectious disease guidelines, as dosing varies significantly. * **Children ≥ 2 years:** * **Dosing for intra-abdominal infections:** 90 mg piperacillin/11.25 mg tazobactam per kg per dose IV every 8 hours. * **Dosing for hospital-acquired pneumonia:** 90 mg piperacillin/11.25 mg tazobactam per kg per dose IV every 6 hours. * **Maximum Dose:** Doses should not exceed the adult maximum of 4.5 grams every 6 hours. * **Weight Limit:** For children weighing > 50 kg, use adult doses. * **Duration:** Varies based on infection and clinical response. ## Dose Adjustments * **Renal Impairment:** * CrCl ≥ 50 mL/min: No dose adjustment necessary. * CrCl 20-49 mL/min: 2.25 grams IV every 6 hours or 3.375 grams IV every 8 hours. * CrCl < 20 mL/min: 2.25 grams IV every 8 hours. * Dose adjustments for pediatric patients with renal impairment should follow specific guidelines. * **Hepatic Impairment:** No specific dose adjustment is recommended, but caution is advised. * **Hemodialysis:** Patients on hemodialysis require dosing after each dialysis session and dose adjustments based on CrCl. ## Contraindications * History of hypersensitivity to piperacillin, tazobactam, other penicillins, or beta-lactams. * History of immediate or severe allergic reaction to amoxicillin/clavulanate. ## Adverse Effects * **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, pruritus, fever, elevated liver enzymes (AST, ALT). * **Serious:** Hypersensitivity reactions (including anaphylaxis), Clostridioides difficile-associated diarrhea, seizures (especially with high doses or renal impairment), neutropenia, thrombocytopenia, interstitial nephritis. ## Key Drug Interactions * **Probenecid:** Can increase and prolong piperacillin-tazobactam serum concentrations. * **Aminoglycosides:** Concurrent use may result in physical or chemical inactivation of piperacillin-tazobactam. If coadministration is necessary, administer separately. * **Neuromuscular blocking agents:** Piperacillin may reduce the effect of vecuronium. Monitor for signs of return of neuromuscular function. * **Warfarin:** May decrease the efficacy of warfarin. Monitor INR closely. ## Monitoring * **Renal function:** Baseline and periodic monitoring, especially in patients with known renal impairment. * **Liver function tests:** Baseline and periodic monitoring. * **Hematologic parameters:** Complete blood count, especially with prolonged therapy. * **Signs of hypersensitivity:** Monitor for rash, itching, or difficulty breathing. * **Signs of C. difficile infection:** Monitor for diarrhea. * **Clinical response:** Assess for improvement in signs and symptoms of infection. ## Clinical Pearls * Piperacillin-tazobactam has broad coverage but is not typically active against MRSA or ESBL-producing organisms. * Reconstitution and further dilution are required before IV administration. Refer to manufacturer's instructions for preparation. * Adjust dose for renal impairment. * Consider extended infusion for critically ill patients to optimize pharmacokinetic/pharmacodynamic targets. * Monitor for hypersensitivity reactions and C. difficile-associated diarrhea. *** **Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant guidelines for complete details and to verify any information before making clinical decisions.